A new request for information asks for comments on dose selection, safety monitoring, eligibility criteria, and oversight approaches to support the responsible development of ibogaine drug products.
|Articles|May 21, 2020
Rho to Coordinate NIAID Sponsored Study to Determine Rate of COVID-19 Infection in U.S. Children
Advertisement
Rho has announced it is coordinating a new study, called Human Epidemiology and Response to SARS-CoV-2 (HEROS), to help determine the rate of the new coronavirus infection in children and their family members in the U.S. The study also aims to determine what percentage of children infected with SARS-CoV-2, develop symptoms of the disease, as well as whether rates of SARS-CoV-2 infection differ between children who have asthma or other allergic conditions and children who do not. HEROS is sponsored and funded by the National Institute of Allergy and Infectious Diseases.
For more information, click
Advertisement
Related to this article
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
Hierarchical composite endpoints analyzed through pairwise comparisons more accurately reflect multifaceted treatment benefit than time-to-first-event composites, but transparent outcome prioritization, patient involvement in ranking, and reporting of Net Treatment Benefit remain underutilized despite their importance to interpretation.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, offers practical guidance for clinical operations teams beginning their AI journey—making the case that the tools are more accessible than many assume and that waiting to start is a competitive risk in itself.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
2
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
3
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
4
ACT Brief: AI Adoption Starting Points, Hierarchical Endpoints and Patient Priorities, and Early-Stage Program Termination
5